pfizer news - Search News

Pfizer, Haleon

Pfizer to sell $3 billion stake in Sensodyne maker Haleon

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner JPMorgan said on Wednesday.

Wall Street Journal · 4h

Pfizer Sells 700 Million Haleon Shares for $3.05 Billion

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.

Business Insider · 19h

Pfizer to sell 700M ordinary shares of Haleon

Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of

Reuters · 19h

Pfizer to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner

Pfizer is looking to sell about 700 million ordinary shares in Haleon , its bookrunner J.P. Morgan said on Tuesday, lowering its stake in the British consumer healthcare company to about 7.3% from 15%.

Seeking Alpha on MSN · 18h

Pfizer to cut Haleon stake in 700M share sale

Pfizer (NYSE:PFE) announced Tuesday it plans to sell roughly 700M ordinary shares in Haleon (NYSE:HLN) to lower its stake in the British consumer healthcare giant from about 15.0% to 7.3%, implying a divestment of approximately 7.

14h

Pfizer appeals denial of $75 million claim in SEC case against Cohen hedge fund

Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider ...

STAT20h

Defiant, Pfizer CEO talks about Trump, obesity drugs, and the ‘Pfizer machine’

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

15h

Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

BioSpace22h

Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

1don MSN

Pfizer CEO Albert Bourla: Our 2025 focus is on pipeline

Albert Bourla, Pfizer chairman and CEO, joins CNBC's 'Power Lunch' to discuss the company's focus for 2025, whether bird flu ...

FiercePharma22h

JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

justthenews1d

Anti-white discrimination lawsuit against Pfizer reinstated after appeals court admits it goofed

Anti-woke medical group not required to unmask its members to challenge fellowship that excludes certain races, 2nd Circuit ...

23h

Pfizer’s Growth Potential and Strategic Focus Justify Buy Rating Amid Healthcare Policy Shifts

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

Hosted on MSN11h

Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Pfizer (PFE) closed at $26.41, marking a -1.46% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.12%. At the same time, the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Pfizer, Haleon

Related topics